These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
244 related articles for article (PubMed ID: 23918069)
41. Healthcare and economic burden of adverse events among patients with chronic myelogenous leukemia treated with BCR-ABL1 tyrosine kinase inhibitors. Lin J; Makenbaeva D; Lingohr-Smith M; Bilmes R J Med Econ; 2017 Jul; 20(7):687-691. PubMed ID: 28287043 [TBL] [Abstract][Full Text] [Related]
42. Vascular Endothelial Growth Factor Receptor Inhibitors Impair Left Ventricular Diastolic Functions. Yokoyama H; Shioyama W; Shintani T; Maeda S; Hirobe S; Maeda M; Sakata Y; Fujio Y Int Heart J; 2021; 62(6):1297-1304. PubMed ID: 34853223 [TBL] [Abstract][Full Text] [Related]
43. Management of tyrosine kinase inhibitors (TKI) side effects in differentiated and medullary thyroid cancer patients. Resteghini C; Cavalieri S; Galbiati D; Granata R; Alfieri S; Bergamini C; Bossi P; Licitra L; Locati LD Best Pract Res Clin Endocrinol Metab; 2017 Jun; 31(3):349-361. PubMed ID: 28911730 [TBL] [Abstract][Full Text] [Related]
44. Cardiovascular effects of tyrosine kinase inhibitors used for gastrointestinal stromal tumors. Chintalgattu V; Patel SS; Khakoo AY Hematol Oncol Clin North Am; 2009 Feb; 23(1):97-107, viii-ix. PubMed ID: 19248973 [TBL] [Abstract][Full Text] [Related]
45. Cardiovascular Toxicity of Tyrosine Kinase Inhibitors Used in Chronic Myeloid Leukemia: An Analysis of the FDA Adverse Event Reporting System Database (FAERS). Cirmi S; El Abd A; Letinier L; Navarra M; Salvo F Cancers (Basel); 2020 Mar; 12(4):. PubMed ID: 32235443 [TBL] [Abstract][Full Text] [Related]
47. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. Schmidinger M; Zielinski CC; Vogl UM; Bojic A; Bojic M; Schukro C; Ruhsam M; Hejna M; Schmidinger H J Clin Oncol; 2008 Nov; 26(32):5204-12. PubMed ID: 18838713 [TBL] [Abstract][Full Text] [Related]
48. Safety profiles of second-line tyrosine kinase inhibitors in patients with chronic myeloid leukaemia. Tinsley SM J Clin Nurs; 2010 May; 19(9-10):1207-18. PubMed ID: 20345830 [TBL] [Abstract][Full Text] [Related]
49. Chinese consensus on management of tyrosine kinase inhibitor-associated side effects in gastrointestinal stromal tumors. Li J; Wang M; Zhang B; Wu X; Lin TL; Liu XF; Zhou Y; Zhang XH; Xu H; Shen LJ; Zou J; Lu P; Zhang D; Gu WJ; Zhang MX; Pan J; Cao H; World J Gastroenterol; 2018 Dec; 24(46):5189-5202. PubMed ID: 30581268 [TBL] [Abstract][Full Text] [Related]
50. Cardiovascular events among 1090 cancer patients treated with sunitinib, interferon, or placebo: a comprehensive adjudicated database analysis demonstrating clinically meaningful reversibility of cardiac events. Ewer MS; Suter TM; Lenihan DJ; Niculescu L; Breazna A; Demetri GD; Motzer RJ Eur J Cancer; 2014 Aug; 50(12):2162-70. PubMed ID: 24930624 [TBL] [Abstract][Full Text] [Related]
51. Tyrosine Kinase Inhibitor-Induced Hypertension. Agarwal M; Thareja N; Benjamin M; Akhondi A; Mitchell GD Curr Oncol Rep; 2018 Jun; 20(8):65. PubMed ID: 29931399 [TBL] [Abstract][Full Text] [Related]
52. The effects of switching EGFR-TKI treatments for non-small cell lung cancer because of adverse events. Sakata Y; Kawamura K; Shingu N; Hiroshige S; Yasuda Y; Eguchi Y; Anan K; Hisanaga J; Nitawaki T; Nakano A; Ichikado K Asia Pac J Clin Oncol; 2020 Apr; 16(2):e113-e117. PubMed ID: 30506897 [TBL] [Abstract][Full Text] [Related]
53. Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta-analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in Advanced EGFR-Mutated Non-Small Cell Lung Cancer. Ding PN; Lord SJ; Gebski V; Links M; Bray V; Gralla RJ; Yang JC; Lee CK J Thorac Oncol; 2017 Apr; 12(4):633-643. PubMed ID: 28007626 [TBL] [Abstract][Full Text] [Related]
54. Four-Dimensional Echocardiographic Evaluation of Left Ventricular Systolic Functions in Patients with Chronic Myeloid Leukaemia Receiving Tyrosine Kinase Inhibitors. Karakulak UN; Aladag E; Hekimsoy V; Sahiner ML; Kaya EB; Ozer N; Aksu S; Demiroglu H; Goker H; Buyukasik Y; Ozcebe O; Sayinalp N; Haznedaroglu IC Cardiovasc Toxicol; 2021 Mar; 21(3):216-223. PubMed ID: 33068232 [TBL] [Abstract][Full Text] [Related]
55. Adverse Cerebral Cardiovascular Events Associated With Checkpoint Kinase 1 Inhibitors: A Systemic Review. Yang T; Gu J; Du C; Shan T; Wei T; Li Y; Wang L J Cardiovasc Pharmacol; 2021 May; 77(5):549-556. PubMed ID: 33951693 [TBL] [Abstract][Full Text] [Related]
56. Clinical characteristics and risk factors of drug-induced lung injury by ALK tyrosine kinase inhibitors: A single center retrospective analysis. Koshikawa K; Terada J; Abe M; Iwasawa S; Sakayori M; Yoshioka K; Hirasawa Y; Kasai H; Kawasaki Y; Tsushima K; Tatsumi K Thorac Cancer; 2020 Jun; 11(6):1495-1502. PubMed ID: 32237210 [TBL] [Abstract][Full Text] [Related]
57. Comparative efficacy and safety of tyrosine kinase inhibitors for thyroid cancer: a systematic review and meta-analysis. Oba T; Chino T; Soma A; Shimizu T; Ono M; Ito T; Kanai T; Maeno K; Ito KI Endocr J; 2020 Dec; 67(12):1215-1226. PubMed ID: 32814730 [TBL] [Abstract][Full Text] [Related]
59. Use of tyrosine kinase inhibitors for chronic myeloid leukemia: management of patients and practical applications for pharmacy practitioners. Wong SF; Mirshahidi H Ann Pharmacother; 2011 Jun; 45(6):787-97. PubMed ID: 21672900 [TBL] [Abstract][Full Text] [Related]
60. Fertility considerations in targeted biologic therapy with tyrosine kinase inhibitors: a review. Rambhatla A; Strug MR; De Paredes JG; Cordoba Munoz MI; Thakur M J Assist Reprod Genet; 2021 Aug; 38(8):1897-1908. PubMed ID: 33826052 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]